Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage
Peter Kolkhof, Elke Hartmann, Alexius Freyberger, et al.
American Journal of Nephrology (2021) Vol. 52, Iss. 8, pp. 642-652
Open Access | Times Cited: 107

Showing 1-25 of 107 citing articles:

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
Rajiv Agarwal, Gerasimos Filippatos, Bertram Pitt, et al.
European Heart Journal (2021) Vol. 43, Iss. 6, pp. 474-484
Open Access | Times Cited: 670
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
Bertram Pitt, Jingmei Li, Rajiv Agarwal, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 24, pp. 2252-2263
Open Access | Times Cited: 446
Molecular mechanisms and therapeutic targets for diabetic kidney disease
Katherine R. Tuttle, Rajiv Agarwal, Charles E. Alpers, et al.
Kidney International (2022) Vol. 102, Iss. 2, pp. 248-260
Open Access | Times Cited: 294
Mineralocorticoid receptor antagonists in diabetic kidney disease — mechanistic and therapeutic effects
Jonatan Barrera‐Chimal, Ixchel Lima‐Posada, George L. Bakris, et al.
Nature Reviews Nephrology (2021) Vol. 18, Iss. 1, pp. 56-70
Closed Access | Times Cited: 153
Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial
Michele Provenzano, María Jesús Puchades, Carlo Garofalo, et al.
Journal of the American Society of Nephrology (2022) Vol. 33, Iss. 8, pp. 1569-1580
Open Access | Times Cited: 116
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis
Peter Rossing, Stefan D. Anker, Gerasimos Filippatos, et al.
Diabetes Care (2022) Vol. 45, Iss. 12, pp. 2991-2998
Open Access | Times Cited: 107
Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression
Sandra Naaman, George L. Bakris
Diabetes Care (2023) Vol. 46, Iss. 9, pp. 1574-1586
Open Access | Times Cited: 106
Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions
Jun Ma, Yanan Li, Xiangyu Yang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 105
Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)
Jennifer B. Green, Amy K. Mottl, George L. Bakris, et al.
Nephrology Dialysis Transplantation (2022) Vol. 38, Iss. 4, pp. 894-903
Open Access | Times Cited: 101
Combination therapy for kidney disease in people with diabetes mellitus
Daniël H. van Raalte, Petter Bjornstad, David Z.I. Cherney, et al.
Nature Reviews Nephrology (2024) Vol. 20, Iss. 7, pp. 433-446
Closed Access | Times Cited: 31
Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression
Na Wang, Chun Zhang
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3086-3086
Open Access | Times Cited: 22
Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders − New perspectives for combination therapy
Peter Kolkhof, Amer Joseph, Ulrich Kintscher
Pharmacological Research (2021) Vol. 172, pp. 105859-105859
Open Access | Times Cited: 56
What’s New in the Molecular Mechanisms of Diabetic Kidney Disease: Recent Advances
Kimio Watanabe, Emiko Sato, Eikan Mishima, et al.
International Journal of Molecular Sciences (2022) Vol. 24, Iss. 1, pp. 570-570
Open Access | Times Cited: 48
Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms
Murray Epstein, Csaba P. Kövesdy, Catherine M. Clase, et al.
American Journal of Kidney Diseases (2022) Vol. 80, Iss. 5, pp. 658-666
Open Access | Times Cited: 47
Hypertension and Type 2 Diabetes—The Novel Treatment Possibilities
Agnieszka Przezak, Weronika Bielka, Andrzej Pawlik
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 12, pp. 6500-6500
Open Access | Times Cited: 41
Cardiorenal benefits of finerenone: protecting kidney and heart
José Ramón González–Juanatey, José Luis Górriz, Alberto Ortíz, et al.
Annals of Medicine (2023) Vol. 55, Iss. 1, pp. 502-513
Open Access | Times Cited: 31
Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
Dong‐Lim Kim, Seung‐Eun Lee, Nan Hee Kim
Endocrinology and Metabolism (2023) Vol. 38, Iss. 1, pp. 43-55
Open Access | Times Cited: 27
Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus
Ruolin Lv, Lili Xu, Lin Che, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 25
Advances in pharmacotherapies for hyperuricemia
Federica Piani, Davide Agnoletti, Claudio Borghi
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 6, pp. 737-745
Closed Access | Times Cited: 25
Finerenone Added to RAS/SGLT2 Blockade for CKD in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3 −/− Mice
Zhihui Zhu, Karoline Rosenkranz, Yoshihiro Kusunoki, et al.
Journal of the American Society of Nephrology (2023) Vol. 34, Iss. 9, pp. 1513-1520
Open Access | Times Cited: 25
Finerenone: First Approval
James E. Frampton
Drugs (2021) Vol. 81, Iss. 15, pp. 1787-1794
Closed Access | Times Cited: 51
The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists
Michele Provenzano, Niels Jongs, Priya Vart, et al.
Kidney International Reports (2021) Vol. 7, Iss. 3, pp. 436-443
Open Access | Times Cited: 51
Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease
Arjun Pandey, Deepak L. Bhatt, Francesco Cosentino, et al.
European Heart Journal (2022) Vol. 43, Iss. 31, pp. 2931-2945
Closed Access | Times Cited: 32
Finerenone: Questions and Answers—The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist
Luca Di Lullo, Carlo Lavalle, Alessia Scatena, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 12, pp. 3992-3992
Open Access | Times Cited: 21
Mineralocorticoid receptor antagonists with sodium–glucose co-transporter-2 inhibitors in heart failure: a meta-analysis
Mainak Banerjee, Indira Maisnam, Rimesh Pal, et al.
European Heart Journal (2023) Vol. 44, Iss. 37, pp. 3686-3696
Open Access | Times Cited: 21
Page 1 - Next Page

Scroll to top